8-K

- --------------------------------------------------------------------------------
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
- --------------------------------------------------------------------------------
                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

                        Date of Report: October 11, 2007
                        (Date of earliest event reported)
- --------------------------------------------------------------------------------

                                  ABIOMED, Inc.
             (Exact name of registrant as specified in its charter)


                   Delaware                                  04-2743260
(State or other Jurisdiction of Incorporation)      (IRS Employer Identification
                                                             Number)

                                     0-20584
                            (Commission File Number)

                              22 Cherry Hill Drive
                                Danvers, MA 01923
          (Address of Principal Executive Offices, including Zip Code)

                                 (978) 646-1400
              (Registrant's Telephone Number, including Area Code)

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)
- --------------------------------------------------------------------------------

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))
- --------------------------------------------------------------------------------



- --------------------------------------------------------------------------------

Item 8.01 Other Events.

     On October 11, 2007 we issued a press release announcing an update on the
510k clearance process for our Impella 2.5 product. A copy of the press release
is set forth as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01   Financial Statements and Exhibits.

      (d) Exhibits

Number       Title
- --------     -------------------------------------------------------------------
99.1         Press Release dated October 11, 2007.



- --------------------------------------------------------------------------------
                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

               ABIOMED, Inc.

               By:  /s/ Daniel J. Sutherby
                    --------------------------------------
                       Daniel J. Sutherby
                       Chief Financial Officer

Date: October 11, 2007

EX-99.1

                                                                    Exhibit 99.1

       Abiomed Announces Update on Impella(R) 2.5 510(k) Process

    DANVERS, Mass.--(BUSINESS WIRE)--Oct. 11, 2007--Abiomed, Inc.
(NASDAQ: ABMD) today announced it recently received a written response
from the U.S. Food and Drug Administration (FDA) outlining four areas
of concern for which they requested additional information related to
the company's submission for 510(k) clearance of the Impella 2.5.

    Two of the questions requested clarification and additional
information related to labeling within the 510(k) submission. A third
question requested additional information related to bench-testing of
the device. A fourth question requested that the company provide an
updated clinical review of the global experience with the Impella 2.5
since the original 510(k) submission, including up to date information
from the U.S. safety pilot clinical trial for the Impella 2.5. The
company plans to respond to this recent request for information.

    "We continue to work diligently with the FDA to provide
clarification on existing data and additional information related to
our 510(k) clearance submission for the Impella 2.5," stated Michael
R. Minogue, Chairman, President and CEO of Abiomed. "While there are
no guarantees for a 510(k) clearance, we remain confident that we are
on a 510(k) path with a potential clearance sometime between November
2007 and March 2008."

    The clinical experience to-date with Impella 2.5 has been
favorable, including its recently completed U.S. safety pilot clinical
trial. The technology is now approved in more than 40 countries, and
is available in Europe under the CE Mark. Impella has been the subject
of more than 20 peer reviewed publications.

    ABOUT ABIOMED

    Based in Danvers, Massachusetts, Abiomed, Inc., is a leading
provider of medical devices that provide circulatory support to acute
heart failure patients across the continuum of care in heart recovery.
Our products are designed to enable the heart to rest, heal and
recover by improving blood flow and/or performing the pumping of the
heart. For additional information please visit: www.abiomed.com.

    FORWARD-LOOKING STATEMENTS

    This Release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and future
opportunities. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a
number of factors, including the Company's ability to provide the FDA
with the additional information it has requested, the results of the
Company's pivotal study, uncertainties associated with development,
testing and related regulatory approvals, anticipated future losses,
complex manufacturing, high quality requirements, dependence on
limited sources of supply, competition, technological change,
government regulation, future capital needs and uncertainty of
additional financing, and other risks and challenges detailed in the
Company's filings with the Securities and Exchange Commission,
including the Annual Report filed on Form 10-K and recently filed Form
10-Q. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
Release. The Company undertakes no obligation to publicly release the
results of any revisions to these forward-looking statements that may
be made to reflect events or circumstances that occur after the date
of this Release or to reflect the occurrence of unanticipated events.

    CONTACT: Abiomed, Inc.
             Daniel J. Sutherby, 978-646-1812
             Chief Financial Officer
             ir@abiomed.com
             or
             Brodeur
             Elizabeth Dumm, 617-817-7951
             Media Relations
             edumm@brodeur.com